Global Large Molecule Drugs CDMO Market 2024 by Company, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Large Molecule Drugs CDMO market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
The Global Info Research report includes an overview of the development of the Large Molecule Drugs CDMO industry chain, the market status of Biological Technology (Cell Line Development, Large Molecule Drug Substance Development), Clinical (Cell Line Development, Large Molecule Drug Substance Development), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Large Molecule Drugs CDMO.
Regionally, the report analyzes the Large Molecule Drugs CDMO markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Large Molecule Drugs CDMO market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Large Molecule Drugs CDMO market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Large Molecule Drugs CDMO industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Cell Line Development, Large Molecule Drug Substance Development).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Large Molecule Drugs CDMO market.
Regional Analysis: The report involves examining the Large Molecule Drugs CDMO market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Large Molecule Drugs CDMO market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Large Molecule Drugs CDMO:
Company Analysis: Report covers individual Large Molecule Drugs CDMO players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Large Molecule Drugs CDMO This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Biological Technology, Clinical).
Technology Analysis: Report covers specific technologies relevant to Large Molecule Drugs CDMO. It assesses the current state, advancements, and potential future developments in Large Molecule Drugs CDMO areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Large Molecule Drugs CDMO market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Large Molecule Drugs CDMO market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chapter 1, to describe Large Molecule Drugs CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Large Molecule Drugs CDMO, with revenue, gross margin and global market share of Large Molecule Drugs CDMO from 2019 to 2024.
Chapter 3, the Large Molecule Drugs CDMO competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Large Molecule Drugs CDMO market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Large Molecule Drugs CDMO.
Chapter 13, to describe Large Molecule Drugs CDMO research findings and conclusion.
The Global Info Research report includes an overview of the development of the Large Molecule Drugs CDMO industry chain, the market status of Biological Technology (Cell Line Development, Large Molecule Drug Substance Development), Clinical (Cell Line Development, Large Molecule Drug Substance Development), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Large Molecule Drugs CDMO.
Regionally, the report analyzes the Large Molecule Drugs CDMO markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Large Molecule Drugs CDMO market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Large Molecule Drugs CDMO market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Large Molecule Drugs CDMO industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Cell Line Development, Large Molecule Drug Substance Development).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Large Molecule Drugs CDMO market.
Regional Analysis: The report involves examining the Large Molecule Drugs CDMO market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Large Molecule Drugs CDMO market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Large Molecule Drugs CDMO:
Company Analysis: Report covers individual Large Molecule Drugs CDMO players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Large Molecule Drugs CDMO This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Biological Technology, Clinical).
Technology Analysis: Report covers specific technologies relevant to Large Molecule Drugs CDMO. It assesses the current state, advancements, and potential future developments in Large Molecule Drugs CDMO areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Large Molecule Drugs CDMO market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Large Molecule Drugs CDMO market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- Cell Line Development
- Large Molecule Drug Substance Development
- Biological Technology
- Clinical
- Pharmaceutical
- Others
- Patheon
- Eurofins Scientific
- Samsung Biologics
- Catalent, Inc.
- Rentschler Biopharma SE
- AGC Biologics
- Recipharm AB
- Siegfried Holding AG
- FUJIFILM Diosynth Biotechnologies
- Scorpius
- Ardena
- Alcami
- Cytiva
- Thermo Fisher Scientific
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Large Molecule Drugs CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Large Molecule Drugs CDMO, with revenue, gross margin and global market share of Large Molecule Drugs CDMO from 2019 to 2024.
Chapter 3, the Large Molecule Drugs CDMO competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Large Molecule Drugs CDMO market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Large Molecule Drugs CDMO.
Chapter 13, to describe Large Molecule Drugs CDMO research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Large Molecule Drugs CDMO
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Large Molecule Drugs CDMO by Type
1.3.1 Overview: Global Large Molecule Drugs CDMO Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Large Molecule Drugs CDMO Consumption Value Market Share by Type in 2023
1.3.3 Cell Line Development
1.3.4 Large Molecule Drug Substance Development
1.4 Global Large Molecule Drugs CDMO Market by Application
1.4.1 Overview: Global Large Molecule Drugs CDMO Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Biological Technology
1.4.3 Clinical
1.4.4 Pharmaceutical
1.4.5 Others
1.5 Global Large Molecule Drugs CDMO Market Size & Forecast
1.6 Global Large Molecule Drugs CDMO Market Size and Forecast by Region
1.6.1 Global Large Molecule Drugs CDMO Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Large Molecule Drugs CDMO Market Size by Region, (2019-2030)
1.6.3 North America Large Molecule Drugs CDMO Market Size and Prospect (2019-2030)
1.6.4 Europe Large Molecule Drugs CDMO Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Large Molecule Drugs CDMO Market Size and Prospect (2019-2030)
1.6.6 South America Large Molecule Drugs CDMO Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Large Molecule Drugs CDMO Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 Patheon
2.1.1 Patheon Details
2.1.2 Patheon Major Business
2.1.3 Patheon Large Molecule Drugs CDMO Product and Solutions
2.1.4 Patheon Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Patheon Recent Developments and Future Plans
2.2 Eurofins Scientific
2.2.1 Eurofins Scientific Details
2.2.2 Eurofins Scientific Major Business
2.2.3 Eurofins Scientific Large Molecule Drugs CDMO Product and Solutions
2.2.4 Eurofins Scientific Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Eurofins Scientific Recent Developments and Future Plans
2.3 Samsung Biologics
2.3.1 Samsung Biologics Details
2.3.2 Samsung Biologics Major Business
2.3.3 Samsung Biologics Large Molecule Drugs CDMO Product and Solutions
2.3.4 Samsung Biologics Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Samsung Biologics Recent Developments and Future Plans
2.4 Catalent, Inc.
2.4.1 Catalent, Inc. Details
2.4.2 Catalent, Inc. Major Business
2.4.3 Catalent, Inc. Large Molecule Drugs CDMO Product and Solutions
2.4.4 Catalent, Inc. Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Catalent, Inc. Recent Developments and Future Plans
2.5 Rentschler Biopharma SE
2.5.1 Rentschler Biopharma SE Details
2.5.2 Rentschler Biopharma SE Major Business
2.5.3 Rentschler Biopharma SE Large Molecule Drugs CDMO Product and Solutions
2.5.4 Rentschler Biopharma SE Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Rentschler Biopharma SE Recent Developments and Future Plans
2.6 AGC Biologics
2.6.1 AGC Biologics Details
2.6.2 AGC Biologics Major Business
2.6.3 AGC Biologics Large Molecule Drugs CDMO Product and Solutions
2.6.4 AGC Biologics Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 AGC Biologics Recent Developments and Future Plans
2.7 Recipharm AB
2.7.1 Recipharm AB Details
2.7.2 Recipharm AB Major Business
2.7.3 Recipharm AB Large Molecule Drugs CDMO Product and Solutions
2.7.4 Recipharm AB Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Recipharm AB Recent Developments and Future Plans
2.8 Siegfried Holding AG
2.8.1 Siegfried Holding AG Details
2.8.2 Siegfried Holding AG Major Business
2.8.3 Siegfried Holding AG Large Molecule Drugs CDMO Product and Solutions
2.8.4 Siegfried Holding AG Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Siegfried Holding AG Recent Developments and Future Plans
2.9 FUJIFILM Diosynth Biotechnologies
2.9.1 FUJIFILM Diosynth Biotechnologies Details
2.9.2 FUJIFILM Diosynth Biotechnologies Major Business
2.9.3 FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Product and Solutions
2.9.4 FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
2.10 Scorpius
2.10.1 Scorpius Details
2.10.2 Scorpius Major Business
2.10.3 Scorpius Large Molecule Drugs CDMO Product and Solutions
2.10.4 Scorpius Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Scorpius Recent Developments and Future Plans
2.11 Ardena
2.11.1 Ardena Details
2.11.2 Ardena Major Business
2.11.3 Ardena Large Molecule Drugs CDMO Product and Solutions
2.11.4 Ardena Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Ardena Recent Developments and Future Plans
2.12 Alcami
2.12.1 Alcami Details
2.12.2 Alcami Major Business
2.12.3 Alcami Large Molecule Drugs CDMO Product and Solutions
2.12.4 Alcami Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Alcami Recent Developments and Future Plans
2.13 Cytiva
2.13.1 Cytiva Details
2.13.2 Cytiva Major Business
2.13.3 Cytiva Large Molecule Drugs CDMO Product and Solutions
2.13.4 Cytiva Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 Cytiva Recent Developments and Future Plans
2.14 Thermo Fisher Scientific
2.14.1 Thermo Fisher Scientific Details
2.14.2 Thermo Fisher Scientific Major Business
2.14.3 Thermo Fisher Scientific Large Molecule Drugs CDMO Product and Solutions
2.14.4 Thermo Fisher Scientific Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.14.5 Thermo Fisher Scientific Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Large Molecule Drugs CDMO Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Large Molecule Drugs CDMO by Company Revenue
3.2.2 Top 3 Large Molecule Drugs CDMO Players Market Share in 2023
3.2.3 Top 6 Large Molecule Drugs CDMO Players Market Share in 2023
3.3 Large Molecule Drugs CDMO Market: Overall Company Footprint Analysis
3.3.1 Large Molecule Drugs CDMO Market: Region Footprint
3.3.2 Large Molecule Drugs CDMO Market: Company Product Type Footprint
3.3.3 Large Molecule Drugs CDMO Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Large Molecule Drugs CDMO Consumption Value and Market Share by Type (2019-2024)
4.2 Global Large Molecule Drugs CDMO Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Large Molecule Drugs CDMO Consumption Value Market Share by Application (2019-2024)
5.2 Global Large Molecule Drugs CDMO Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Large Molecule Drugs CDMO Consumption Value by Type (2019-2030)
6.2 North America Large Molecule Drugs CDMO Consumption Value by Application (2019-2030)
6.3 North America Large Molecule Drugs CDMO Market Size by Country
6.3.1 North America Large Molecule Drugs CDMO Consumption Value by Country (2019-2030)
6.3.2 United States Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
6.3.3 Canada Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
6.3.4 Mexico Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Large Molecule Drugs CDMO Consumption Value by Type (2019-2030)
7.2 Europe Large Molecule Drugs CDMO Consumption Value by Application (2019-2030)
7.3 Europe Large Molecule Drugs CDMO Market Size by Country
7.3.1 Europe Large Molecule Drugs CDMO Consumption Value by Country (2019-2030)
7.3.2 Germany Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
7.3.3 France Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
7.3.5 Russia Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
7.3.6 Italy Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Large Molecule Drugs CDMO Market Size by Region
8.3.1 Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Region (2019-2030)
8.3.2 China Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
8.3.3 Japan Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
8.3.4 South Korea Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
8.3.5 India Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
8.3.7 Australia Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Large Molecule Drugs CDMO Consumption Value by Type (2019-2030)
9.2 South America Large Molecule Drugs CDMO Consumption Value by Application (2019-2030)
9.3 South America Large Molecule Drugs CDMO Market Size by Country
9.3.1 South America Large Molecule Drugs CDMO Consumption Value by Country (2019-2030)
9.3.2 Brazil Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
9.3.3 Argentina Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Large Molecule Drugs CDMO Market Size by Country
10.3.1 Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Country (2019-2030)
10.3.2 Turkey Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
10.3.4 UAE Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Large Molecule Drugs CDMO Market Drivers
11.2 Large Molecule Drugs CDMO Market Restraints
11.3 Large Molecule Drugs CDMO Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Large Molecule Drugs CDMO Industry Chain
12.2 Large Molecule Drugs CDMO Upstream Analysis
12.3 Large Molecule Drugs CDMO Midstream Analysis
12.4 Large Molecule Drugs CDMO Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Large Molecule Drugs CDMO
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Large Molecule Drugs CDMO by Type
1.3.1 Overview: Global Large Molecule Drugs CDMO Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Large Molecule Drugs CDMO Consumption Value Market Share by Type in 2023
1.3.3 Cell Line Development
1.3.4 Large Molecule Drug Substance Development
1.4 Global Large Molecule Drugs CDMO Market by Application
1.4.1 Overview: Global Large Molecule Drugs CDMO Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Biological Technology
1.4.3 Clinical
1.4.4 Pharmaceutical
1.4.5 Others
1.5 Global Large Molecule Drugs CDMO Market Size & Forecast
1.6 Global Large Molecule Drugs CDMO Market Size and Forecast by Region
1.6.1 Global Large Molecule Drugs CDMO Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Large Molecule Drugs CDMO Market Size by Region, (2019-2030)
1.6.3 North America Large Molecule Drugs CDMO Market Size and Prospect (2019-2030)
1.6.4 Europe Large Molecule Drugs CDMO Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Large Molecule Drugs CDMO Market Size and Prospect (2019-2030)
1.6.6 South America Large Molecule Drugs CDMO Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Large Molecule Drugs CDMO Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 Patheon
2.1.1 Patheon Details
2.1.2 Patheon Major Business
2.1.3 Patheon Large Molecule Drugs CDMO Product and Solutions
2.1.4 Patheon Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Patheon Recent Developments and Future Plans
2.2 Eurofins Scientific
2.2.1 Eurofins Scientific Details
2.2.2 Eurofins Scientific Major Business
2.2.3 Eurofins Scientific Large Molecule Drugs CDMO Product and Solutions
2.2.4 Eurofins Scientific Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Eurofins Scientific Recent Developments and Future Plans
2.3 Samsung Biologics
2.3.1 Samsung Biologics Details
2.3.2 Samsung Biologics Major Business
2.3.3 Samsung Biologics Large Molecule Drugs CDMO Product and Solutions
2.3.4 Samsung Biologics Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Samsung Biologics Recent Developments and Future Plans
2.4 Catalent, Inc.
2.4.1 Catalent, Inc. Details
2.4.2 Catalent, Inc. Major Business
2.4.3 Catalent, Inc. Large Molecule Drugs CDMO Product and Solutions
2.4.4 Catalent, Inc. Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Catalent, Inc. Recent Developments and Future Plans
2.5 Rentschler Biopharma SE
2.5.1 Rentschler Biopharma SE Details
2.5.2 Rentschler Biopharma SE Major Business
2.5.3 Rentschler Biopharma SE Large Molecule Drugs CDMO Product and Solutions
2.5.4 Rentschler Biopharma SE Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Rentschler Biopharma SE Recent Developments and Future Plans
2.6 AGC Biologics
2.6.1 AGC Biologics Details
2.6.2 AGC Biologics Major Business
2.6.3 AGC Biologics Large Molecule Drugs CDMO Product and Solutions
2.6.4 AGC Biologics Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 AGC Biologics Recent Developments and Future Plans
2.7 Recipharm AB
2.7.1 Recipharm AB Details
2.7.2 Recipharm AB Major Business
2.7.3 Recipharm AB Large Molecule Drugs CDMO Product and Solutions
2.7.4 Recipharm AB Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Recipharm AB Recent Developments and Future Plans
2.8 Siegfried Holding AG
2.8.1 Siegfried Holding AG Details
2.8.2 Siegfried Holding AG Major Business
2.8.3 Siegfried Holding AG Large Molecule Drugs CDMO Product and Solutions
2.8.4 Siegfried Holding AG Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Siegfried Holding AG Recent Developments and Future Plans
2.9 FUJIFILM Diosynth Biotechnologies
2.9.1 FUJIFILM Diosynth Biotechnologies Details
2.9.2 FUJIFILM Diosynth Biotechnologies Major Business
2.9.3 FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Product and Solutions
2.9.4 FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
2.10 Scorpius
2.10.1 Scorpius Details
2.10.2 Scorpius Major Business
2.10.3 Scorpius Large Molecule Drugs CDMO Product and Solutions
2.10.4 Scorpius Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Scorpius Recent Developments and Future Plans
2.11 Ardena
2.11.1 Ardena Details
2.11.2 Ardena Major Business
2.11.3 Ardena Large Molecule Drugs CDMO Product and Solutions
2.11.4 Ardena Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Ardena Recent Developments and Future Plans
2.12 Alcami
2.12.1 Alcami Details
2.12.2 Alcami Major Business
2.12.3 Alcami Large Molecule Drugs CDMO Product and Solutions
2.12.4 Alcami Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Alcami Recent Developments and Future Plans
2.13 Cytiva
2.13.1 Cytiva Details
2.13.2 Cytiva Major Business
2.13.3 Cytiva Large Molecule Drugs CDMO Product and Solutions
2.13.4 Cytiva Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 Cytiva Recent Developments and Future Plans
2.14 Thermo Fisher Scientific
2.14.1 Thermo Fisher Scientific Details
2.14.2 Thermo Fisher Scientific Major Business
2.14.3 Thermo Fisher Scientific Large Molecule Drugs CDMO Product and Solutions
2.14.4 Thermo Fisher Scientific Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
2.14.5 Thermo Fisher Scientific Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Large Molecule Drugs CDMO Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Large Molecule Drugs CDMO by Company Revenue
3.2.2 Top 3 Large Molecule Drugs CDMO Players Market Share in 2023
3.2.3 Top 6 Large Molecule Drugs CDMO Players Market Share in 2023
3.3 Large Molecule Drugs CDMO Market: Overall Company Footprint Analysis
3.3.1 Large Molecule Drugs CDMO Market: Region Footprint
3.3.2 Large Molecule Drugs CDMO Market: Company Product Type Footprint
3.3.3 Large Molecule Drugs CDMO Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Large Molecule Drugs CDMO Consumption Value and Market Share by Type (2019-2024)
4.2 Global Large Molecule Drugs CDMO Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Large Molecule Drugs CDMO Consumption Value Market Share by Application (2019-2024)
5.2 Global Large Molecule Drugs CDMO Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Large Molecule Drugs CDMO Consumption Value by Type (2019-2030)
6.2 North America Large Molecule Drugs CDMO Consumption Value by Application (2019-2030)
6.3 North America Large Molecule Drugs CDMO Market Size by Country
6.3.1 North America Large Molecule Drugs CDMO Consumption Value by Country (2019-2030)
6.3.2 United States Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
6.3.3 Canada Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
6.3.4 Mexico Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Large Molecule Drugs CDMO Consumption Value by Type (2019-2030)
7.2 Europe Large Molecule Drugs CDMO Consumption Value by Application (2019-2030)
7.3 Europe Large Molecule Drugs CDMO Market Size by Country
7.3.1 Europe Large Molecule Drugs CDMO Consumption Value by Country (2019-2030)
7.3.2 Germany Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
7.3.3 France Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
7.3.5 Russia Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
7.3.6 Italy Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Large Molecule Drugs CDMO Market Size by Region
8.3.1 Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Region (2019-2030)
8.3.2 China Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
8.3.3 Japan Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
8.3.4 South Korea Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
8.3.5 India Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
8.3.7 Australia Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Large Molecule Drugs CDMO Consumption Value by Type (2019-2030)
9.2 South America Large Molecule Drugs CDMO Consumption Value by Application (2019-2030)
9.3 South America Large Molecule Drugs CDMO Market Size by Country
9.3.1 South America Large Molecule Drugs CDMO Consumption Value by Country (2019-2030)
9.3.2 Brazil Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
9.3.3 Argentina Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Large Molecule Drugs CDMO Market Size by Country
10.3.1 Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Country (2019-2030)
10.3.2 Turkey Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
10.3.4 UAE Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Large Molecule Drugs CDMO Market Drivers
11.2 Large Molecule Drugs CDMO Market Restraints
11.3 Large Molecule Drugs CDMO Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Large Molecule Drugs CDMO Industry Chain
12.2 Large Molecule Drugs CDMO Upstream Analysis
12.3 Large Molecule Drugs CDMO Midstream Analysis
12.4 Large Molecule Drugs CDMO Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Large Molecule Drugs CDMO Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Large Molecule Drugs CDMO Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Large Molecule Drugs CDMO Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Large Molecule Drugs CDMO Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Patheon Company Information, Head Office, and Major Competitors
Table 6. Patheon Major Business
Table 7. Patheon Large Molecule Drugs CDMO Product and Solutions
Table 8. Patheon Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Patheon Recent Developments and Future Plans
Table 10. Eurofins Scientific Company Information, Head Office, and Major Competitors
Table 11. Eurofins Scientific Major Business
Table 12. Eurofins Scientific Large Molecule Drugs CDMO Product and Solutions
Table 13. Eurofins Scientific Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. Eurofins Scientific Recent Developments and Future Plans
Table 15. Samsung Biologics Company Information, Head Office, and Major Competitors
Table 16. Samsung Biologics Major Business
Table 17. Samsung Biologics Large Molecule Drugs CDMO Product and Solutions
Table 18. Samsung Biologics Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Samsung Biologics Recent Developments and Future Plans
Table 20. Catalent, Inc. Company Information, Head Office, and Major Competitors
Table 21. Catalent, Inc. Major Business
Table 22. Catalent, Inc. Large Molecule Drugs CDMO Product and Solutions
Table 23. Catalent, Inc. Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. Catalent, Inc. Recent Developments and Future Plans
Table 25. Rentschler Biopharma SE Company Information, Head Office, and Major Competitors
Table 26. Rentschler Biopharma SE Major Business
Table 27. Rentschler Biopharma SE Large Molecule Drugs CDMO Product and Solutions
Table 28. Rentschler Biopharma SE Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Rentschler Biopharma SE Recent Developments and Future Plans
Table 30. AGC Biologics Company Information, Head Office, and Major Competitors
Table 31. AGC Biologics Major Business
Table 32. AGC Biologics Large Molecule Drugs CDMO Product and Solutions
Table 33. AGC Biologics Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. AGC Biologics Recent Developments and Future Plans
Table 35. Recipharm AB Company Information, Head Office, and Major Competitors
Table 36. Recipharm AB Major Business
Table 37. Recipharm AB Large Molecule Drugs CDMO Product and Solutions
Table 38. Recipharm AB Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Recipharm AB Recent Developments and Future Plans
Table 40. Siegfried Holding AG Company Information, Head Office, and Major Competitors
Table 41. Siegfried Holding AG Major Business
Table 42. Siegfried Holding AG Large Molecule Drugs CDMO Product and Solutions
Table 43. Siegfried Holding AG Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Siegfried Holding AG Recent Developments and Future Plans
Table 45. FUJIFILM Diosynth Biotechnologies Company Information, Head Office, and Major Competitors
Table 46. FUJIFILM Diosynth Biotechnologies Major Business
Table 47. FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Product and Solutions
Table 48. FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
Table 50. Scorpius Company Information, Head Office, and Major Competitors
Table 51. Scorpius Major Business
Table 52. Scorpius Large Molecule Drugs CDMO Product and Solutions
Table 53. Scorpius Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. Scorpius Recent Developments and Future Plans
Table 55. Ardena Company Information, Head Office, and Major Competitors
Table 56. Ardena Major Business
Table 57. Ardena Large Molecule Drugs CDMO Product and Solutions
Table 58. Ardena Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 59. Ardena Recent Developments and Future Plans
Table 60. Alcami Company Information, Head Office, and Major Competitors
Table 61. Alcami Major Business
Table 62. Alcami Large Molecule Drugs CDMO Product and Solutions
Table 63. Alcami Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 64. Alcami Recent Developments and Future Plans
Table 65. Cytiva Company Information, Head Office, and Major Competitors
Table 66. Cytiva Major Business
Table 67. Cytiva Large Molecule Drugs CDMO Product and Solutions
Table 68. Cytiva Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 69. Cytiva Recent Developments and Future Plans
Table 70. Thermo Fisher Scientific Company Information, Head Office, and Major Competitors
Table 71. Thermo Fisher Scientific Major Business
Table 72. Thermo Fisher Scientific Large Molecule Drugs CDMO Product and Solutions
Table 73. Thermo Fisher Scientific Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 74. Thermo Fisher Scientific Recent Developments and Future Plans
Table 75. Global Large Molecule Drugs CDMO Revenue (USD Million) by Players (2019-2024)
Table 76. Global Large Molecule Drugs CDMO Revenue Share by Players (2019-2024)
Table 77. Breakdown of Large Molecule Drugs CDMO by Company Type (Tier 1, Tier 2, and Tier 3)
Table 78. Market Position of Players in Large Molecule Drugs CDMO, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 79. Head Office of Key Large Molecule Drugs CDMO Players
Table 80. Large Molecule Drugs CDMO Market: Company Product Type Footprint
Table 81. Large Molecule Drugs CDMO Market: Company Product Application Footprint
Table 82. Large Molecule Drugs CDMO New Market Entrants and Barriers to Market Entry
Table 83. Large Molecule Drugs CDMO Mergers, Acquisition, Agreements, and Collaborations
Table 84. Global Large Molecule Drugs CDMO Consumption Value (USD Million) by Type (2019-2024)
Table 85. Global Large Molecule Drugs CDMO Consumption Value Share by Type (2019-2024)
Table 86. Global Large Molecule Drugs CDMO Consumption Value Forecast by Type (2025-2030)
Table 87. Global Large Molecule Drugs CDMO Consumption Value by Application (2019-2024)
Table 88. Global Large Molecule Drugs CDMO Consumption Value Forecast by Application (2025-2030)
Table 89. North America Large Molecule Drugs CDMO Consumption Value by Type (2019-2024) & (USD Million)
Table 90. North America Large Molecule Drugs CDMO Consumption Value by Type (2025-2030) & (USD Million)
Table 91. North America Large Molecule Drugs CDMO Consumption Value by Application (2019-2024) & (USD Million)
Table 92. North America Large Molecule Drugs CDMO Consumption Value by Application (2025-2030) & (USD Million)
Table 93. North America Large Molecule Drugs CDMO Consumption Value by Country (2019-2024) & (USD Million)
Table 94. North America Large Molecule Drugs CDMO Consumption Value by Country (2025-2030) & (USD Million)
Table 95. Europe Large Molecule Drugs CDMO Consumption Value by Type (2019-2024) & (USD Million)
Table 96. Europe Large Molecule Drugs CDMO Consumption Value by Type (2025-2030) & (USD Million)
Table 97. Europe Large Molecule Drugs CDMO Consumption Value by Application (2019-2024) & (USD Million)
Table 98. Europe Large Molecule Drugs CDMO Consumption Value by Application (2025-2030) & (USD Million)
Table 99. Europe Large Molecule Drugs CDMO Consumption Value by Country (2019-2024) & (USD Million)
Table 100. Europe Large Molecule Drugs CDMO Consumption Value by Country (2025-2030) & (USD Million)
Table 101. Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Type (2019-2024) & (USD Million)
Table 102. Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Type (2025-2030) & (USD Million)
Table 103. Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Application (2019-2024) & (USD Million)
Table 104. Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Application (2025-2030) & (USD Million)
Table 105. Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Region (2019-2024) & (USD Million)
Table 106. Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Region (2025-2030) & (USD Million)
Table 107. South America Large Molecule Drugs CDMO Consumption Value by Type (2019-2024) & (USD Million)
Table 108. South America Large Molecule Drugs CDMO Consumption Value by Type (2025-2030) & (USD Million)
Table 109. South America Large Molecule Drugs CDMO Consumption Value by Application (2019-2024) & (USD Million)
Table 110. South America Large Molecule Drugs CDMO Consumption Value by Application (2025-2030) & (USD Million)
Table 111. South America Large Molecule Drugs CDMO Consumption Value by Country (2019-2024) & (USD Million)
Table 112. South America Large Molecule Drugs CDMO Consumption Value by Country (2025-2030) & (USD Million)
Table 113. Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Type (2019-2024) & (USD Million)
Table 114. Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Type (2025-2030) & (USD Million)
Table 115. Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Application (2019-2024) & (USD Million)
Table 116. Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Application (2025-2030) & (USD Million)
Table 117. Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Country (2019-2024) & (USD Million)
Table 118. Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Country (2025-2030) & (USD Million)
Table 119. Large Molecule Drugs CDMO Raw Material
Table 120. Key Suppliers of Large Molecule Drugs CDMO Raw Materials
LIST OF FIGURE
s
Figure 1. Large Molecule Drugs CDMO Picture
Figure 2. Global Large Molecule Drugs CDMO Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Large Molecule Drugs CDMO Consumption Value Market Share by Type in 2023
Figure 4. Cell Line Development
Figure 5. Large Molecule Drug Substance Development
Figure 6. Global Large Molecule Drugs CDMO Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 7. Large Molecule Drugs CDMO Consumption Value Market Share by Application in 2023
Figure 8. Biological Technology Picture
Figure 9. Clinical Picture
Figure 10. Pharmaceutical Picture
Figure 11. Others Picture
Figure 12. Global Large Molecule Drugs CDMO Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 13. Global Large Molecule Drugs CDMO Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 14. Global Market Large Molecule Drugs CDMO Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 15. Global Large Molecule Drugs CDMO Consumption Value Market Share by Region (2019-2030)
Figure 16. Global Large Molecule Drugs CDMO Consumption Value Market Share by Region in 2023
Figure 17. North America Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 18. Europe Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 19. Asia-Pacific Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 20. South America Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 21. Middle East and Africa Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 22. Global Large Molecule Drugs CDMO Revenue Share by Players in 2023
Figure 23. Large Molecule Drugs CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 24. Global Top 3 Players Large Molecule Drugs CDMO Market Share in 2023
Figure 25. Global Top 6 Players Large Molecule Drugs CDMO Market Share in 2023
Figure 26. Global Large Molecule Drugs CDMO Consumption Value Share by Type (2019-2024)
Figure 27. Global Large Molecule Drugs CDMO Market Share Forecast by Type (2025-2030)
Figure 28. Global Large Molecule Drugs CDMO Consumption Value Share by Application (2019-2024)
Figure 29. Global Large Molecule Drugs CDMO Market Share Forecast by Application (2025-2030)
Figure 30. North America Large Molecule Drugs CDMO Consumption Value Market Share by Type (2019-2030)
Figure 31. North America Large Molecule Drugs CDMO Consumption Value Market Share by Application (2019-2030)
Figure 32. North America Large Molecule Drugs CDMO Consumption Value Market Share by Country (2019-2030)
Figure 33. United States Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 34. Canada Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 35. Mexico Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 36. Europe Large Molecule Drugs CDMO Consumption Value Market Share by Type (2019-2030)
Figure 37. Europe Large Molecule Drugs CDMO Consumption Value Market Share by Application (2019-2030)
Figure 38. Europe Large Molecule Drugs CDMO Consumption Value Market Share by Country (2019-2030)
Figure 39. Germany Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 40. France Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 41. United Kingdom Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 42. Russia Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 43. Italy Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 44. Asia-Pacific Large Molecule Drugs CDMO Consumption Value Market Share by Type (2019-2030)
Figure 45. Asia-Pacific Large Molecule Drugs CDMO Consumption Value Market Share by Application (2019-2030)
Figure 46. Asia-Pacific Large Molecule Drugs CDMO Consumption Value Market Share by Region (2019-2030)
Figure 47. China Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 48. Japan Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 49. South Korea Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 50. India Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 51. Southeast Asia Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 52. Australia Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 53. South America Large Molecule Drugs CDMO Consumption Value Market Share by Type (2019-2030)
Figure 54. South America Large Molecule Drugs CDMO Consumption Value Market Share by Application (2019-2030)
Figure 55. South America Large Molecule Drugs CDMO Consumption Value Market Share by Country (2019-2030)
Figure 56. Brazil Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 57. Argentina Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 58. Middle East and Africa Large Molecule Drugs CDMO Consumption Value Market Share by Type (2019-2030)
Figure 59. Middle East and Africa Large Molecule Drugs CDMO Consumption Value Market Share by Application (2019-2030)
Figure 60. Middle East and Africa Large Molecule Drugs CDMO Consumption Value Market Share by Country (2019-2030)
Figure 61. Turkey Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 62. Saudi Arabia Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 63. UAE Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 64. Large Molecule Drugs CDMO Market Drivers
Figure 65. Large Molecule Drugs CDMO Market Restraints
Figure 66. Large Molecule Drugs CDMO Market Trends
Figure 67. Porters Five Forces Analysis
Figure 68. Manufacturing Cost Structure Analysis of Large Molecule Drugs CDMO in 2023
Figure 69. Manufacturing Process Analysis of Large Molecule Drugs CDMO
Figure 70. Large Molecule Drugs CDMO Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
Table 1. Global Large Molecule Drugs CDMO Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Large Molecule Drugs CDMO Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Large Molecule Drugs CDMO Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Large Molecule Drugs CDMO Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Patheon Company Information, Head Office, and Major Competitors
Table 6. Patheon Major Business
Table 7. Patheon Large Molecule Drugs CDMO Product and Solutions
Table 8. Patheon Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Patheon Recent Developments and Future Plans
Table 10. Eurofins Scientific Company Information, Head Office, and Major Competitors
Table 11. Eurofins Scientific Major Business
Table 12. Eurofins Scientific Large Molecule Drugs CDMO Product and Solutions
Table 13. Eurofins Scientific Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. Eurofins Scientific Recent Developments and Future Plans
Table 15. Samsung Biologics Company Information, Head Office, and Major Competitors
Table 16. Samsung Biologics Major Business
Table 17. Samsung Biologics Large Molecule Drugs CDMO Product and Solutions
Table 18. Samsung Biologics Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Samsung Biologics Recent Developments and Future Plans
Table 20. Catalent, Inc. Company Information, Head Office, and Major Competitors
Table 21. Catalent, Inc. Major Business
Table 22. Catalent, Inc. Large Molecule Drugs CDMO Product and Solutions
Table 23. Catalent, Inc. Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. Catalent, Inc. Recent Developments and Future Plans
Table 25. Rentschler Biopharma SE Company Information, Head Office, and Major Competitors
Table 26. Rentschler Biopharma SE Major Business
Table 27. Rentschler Biopharma SE Large Molecule Drugs CDMO Product and Solutions
Table 28. Rentschler Biopharma SE Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Rentschler Biopharma SE Recent Developments and Future Plans
Table 30. AGC Biologics Company Information, Head Office, and Major Competitors
Table 31. AGC Biologics Major Business
Table 32. AGC Biologics Large Molecule Drugs CDMO Product and Solutions
Table 33. AGC Biologics Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. AGC Biologics Recent Developments and Future Plans
Table 35. Recipharm AB Company Information, Head Office, and Major Competitors
Table 36. Recipharm AB Major Business
Table 37. Recipharm AB Large Molecule Drugs CDMO Product and Solutions
Table 38. Recipharm AB Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Recipharm AB Recent Developments and Future Plans
Table 40. Siegfried Holding AG Company Information, Head Office, and Major Competitors
Table 41. Siegfried Holding AG Major Business
Table 42. Siegfried Holding AG Large Molecule Drugs CDMO Product and Solutions
Table 43. Siegfried Holding AG Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Siegfried Holding AG Recent Developments and Future Plans
Table 45. FUJIFILM Diosynth Biotechnologies Company Information, Head Office, and Major Competitors
Table 46. FUJIFILM Diosynth Biotechnologies Major Business
Table 47. FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Product and Solutions
Table 48. FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
Table 50. Scorpius Company Information, Head Office, and Major Competitors
Table 51. Scorpius Major Business
Table 52. Scorpius Large Molecule Drugs CDMO Product and Solutions
Table 53. Scorpius Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. Scorpius Recent Developments and Future Plans
Table 55. Ardena Company Information, Head Office, and Major Competitors
Table 56. Ardena Major Business
Table 57. Ardena Large Molecule Drugs CDMO Product and Solutions
Table 58. Ardena Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 59. Ardena Recent Developments and Future Plans
Table 60. Alcami Company Information, Head Office, and Major Competitors
Table 61. Alcami Major Business
Table 62. Alcami Large Molecule Drugs CDMO Product and Solutions
Table 63. Alcami Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 64. Alcami Recent Developments and Future Plans
Table 65. Cytiva Company Information, Head Office, and Major Competitors
Table 66. Cytiva Major Business
Table 67. Cytiva Large Molecule Drugs CDMO Product and Solutions
Table 68. Cytiva Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 69. Cytiva Recent Developments and Future Plans
Table 70. Thermo Fisher Scientific Company Information, Head Office, and Major Competitors
Table 71. Thermo Fisher Scientific Major Business
Table 72. Thermo Fisher Scientific Large Molecule Drugs CDMO Product and Solutions
Table 73. Thermo Fisher Scientific Large Molecule Drugs CDMO Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 74. Thermo Fisher Scientific Recent Developments and Future Plans
Table 75. Global Large Molecule Drugs CDMO Revenue (USD Million) by Players (2019-2024)
Table 76. Global Large Molecule Drugs CDMO Revenue Share by Players (2019-2024)
Table 77. Breakdown of Large Molecule Drugs CDMO by Company Type (Tier 1, Tier 2, and Tier 3)
Table 78. Market Position of Players in Large Molecule Drugs CDMO, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 79. Head Office of Key Large Molecule Drugs CDMO Players
Table 80. Large Molecule Drugs CDMO Market: Company Product Type Footprint
Table 81. Large Molecule Drugs CDMO Market: Company Product Application Footprint
Table 82. Large Molecule Drugs CDMO New Market Entrants and Barriers to Market Entry
Table 83. Large Molecule Drugs CDMO Mergers, Acquisition, Agreements, and Collaborations
Table 84. Global Large Molecule Drugs CDMO Consumption Value (USD Million) by Type (2019-2024)
Table 85. Global Large Molecule Drugs CDMO Consumption Value Share by Type (2019-2024)
Table 86. Global Large Molecule Drugs CDMO Consumption Value Forecast by Type (2025-2030)
Table 87. Global Large Molecule Drugs CDMO Consumption Value by Application (2019-2024)
Table 88. Global Large Molecule Drugs CDMO Consumption Value Forecast by Application (2025-2030)
Table 89. North America Large Molecule Drugs CDMO Consumption Value by Type (2019-2024) & (USD Million)
Table 90. North America Large Molecule Drugs CDMO Consumption Value by Type (2025-2030) & (USD Million)
Table 91. North America Large Molecule Drugs CDMO Consumption Value by Application (2019-2024) & (USD Million)
Table 92. North America Large Molecule Drugs CDMO Consumption Value by Application (2025-2030) & (USD Million)
Table 93. North America Large Molecule Drugs CDMO Consumption Value by Country (2019-2024) & (USD Million)
Table 94. North America Large Molecule Drugs CDMO Consumption Value by Country (2025-2030) & (USD Million)
Table 95. Europe Large Molecule Drugs CDMO Consumption Value by Type (2019-2024) & (USD Million)
Table 96. Europe Large Molecule Drugs CDMO Consumption Value by Type (2025-2030) & (USD Million)
Table 97. Europe Large Molecule Drugs CDMO Consumption Value by Application (2019-2024) & (USD Million)
Table 98. Europe Large Molecule Drugs CDMO Consumption Value by Application (2025-2030) & (USD Million)
Table 99. Europe Large Molecule Drugs CDMO Consumption Value by Country (2019-2024) & (USD Million)
Table 100. Europe Large Molecule Drugs CDMO Consumption Value by Country (2025-2030) & (USD Million)
Table 101. Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Type (2019-2024) & (USD Million)
Table 102. Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Type (2025-2030) & (USD Million)
Table 103. Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Application (2019-2024) & (USD Million)
Table 104. Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Application (2025-2030) & (USD Million)
Table 105. Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Region (2019-2024) & (USD Million)
Table 106. Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Region (2025-2030) & (USD Million)
Table 107. South America Large Molecule Drugs CDMO Consumption Value by Type (2019-2024) & (USD Million)
Table 108. South America Large Molecule Drugs CDMO Consumption Value by Type (2025-2030) & (USD Million)
Table 109. South America Large Molecule Drugs CDMO Consumption Value by Application (2019-2024) & (USD Million)
Table 110. South America Large Molecule Drugs CDMO Consumption Value by Application (2025-2030) & (USD Million)
Table 111. South America Large Molecule Drugs CDMO Consumption Value by Country (2019-2024) & (USD Million)
Table 112. South America Large Molecule Drugs CDMO Consumption Value by Country (2025-2030) & (USD Million)
Table 113. Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Type (2019-2024) & (USD Million)
Table 114. Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Type (2025-2030) & (USD Million)
Table 115. Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Application (2019-2024) & (USD Million)
Table 116. Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Application (2025-2030) & (USD Million)
Table 117. Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Country (2019-2024) & (USD Million)
Table 118. Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Country (2025-2030) & (USD Million)
Table 119. Large Molecule Drugs CDMO Raw Material
Table 120. Key Suppliers of Large Molecule Drugs CDMO Raw Materials
LIST OF FIGURE
s
Figure 1. Large Molecule Drugs CDMO Picture
Figure 2. Global Large Molecule Drugs CDMO Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Large Molecule Drugs CDMO Consumption Value Market Share by Type in 2023
Figure 4. Cell Line Development
Figure 5. Large Molecule Drug Substance Development
Figure 6. Global Large Molecule Drugs CDMO Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 7. Large Molecule Drugs CDMO Consumption Value Market Share by Application in 2023
Figure 8. Biological Technology Picture
Figure 9. Clinical Picture
Figure 10. Pharmaceutical Picture
Figure 11. Others Picture
Figure 12. Global Large Molecule Drugs CDMO Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 13. Global Large Molecule Drugs CDMO Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 14. Global Market Large Molecule Drugs CDMO Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 15. Global Large Molecule Drugs CDMO Consumption Value Market Share by Region (2019-2030)
Figure 16. Global Large Molecule Drugs CDMO Consumption Value Market Share by Region in 2023
Figure 17. North America Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 18. Europe Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 19. Asia-Pacific Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 20. South America Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 21. Middle East and Africa Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 22. Global Large Molecule Drugs CDMO Revenue Share by Players in 2023
Figure 23. Large Molecule Drugs CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 24. Global Top 3 Players Large Molecule Drugs CDMO Market Share in 2023
Figure 25. Global Top 6 Players Large Molecule Drugs CDMO Market Share in 2023
Figure 26. Global Large Molecule Drugs CDMO Consumption Value Share by Type (2019-2024)
Figure 27. Global Large Molecule Drugs CDMO Market Share Forecast by Type (2025-2030)
Figure 28. Global Large Molecule Drugs CDMO Consumption Value Share by Application (2019-2024)
Figure 29. Global Large Molecule Drugs CDMO Market Share Forecast by Application (2025-2030)
Figure 30. North America Large Molecule Drugs CDMO Consumption Value Market Share by Type (2019-2030)
Figure 31. North America Large Molecule Drugs CDMO Consumption Value Market Share by Application (2019-2030)
Figure 32. North America Large Molecule Drugs CDMO Consumption Value Market Share by Country (2019-2030)
Figure 33. United States Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 34. Canada Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 35. Mexico Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 36. Europe Large Molecule Drugs CDMO Consumption Value Market Share by Type (2019-2030)
Figure 37. Europe Large Molecule Drugs CDMO Consumption Value Market Share by Application (2019-2030)
Figure 38. Europe Large Molecule Drugs CDMO Consumption Value Market Share by Country (2019-2030)
Figure 39. Germany Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 40. France Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 41. United Kingdom Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 42. Russia Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 43. Italy Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 44. Asia-Pacific Large Molecule Drugs CDMO Consumption Value Market Share by Type (2019-2030)
Figure 45. Asia-Pacific Large Molecule Drugs CDMO Consumption Value Market Share by Application (2019-2030)
Figure 46. Asia-Pacific Large Molecule Drugs CDMO Consumption Value Market Share by Region (2019-2030)
Figure 47. China Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 48. Japan Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 49. South Korea Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 50. India Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 51. Southeast Asia Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 52. Australia Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 53. South America Large Molecule Drugs CDMO Consumption Value Market Share by Type (2019-2030)
Figure 54. South America Large Molecule Drugs CDMO Consumption Value Market Share by Application (2019-2030)
Figure 55. South America Large Molecule Drugs CDMO Consumption Value Market Share by Country (2019-2030)
Figure 56. Brazil Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 57. Argentina Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 58. Middle East and Africa Large Molecule Drugs CDMO Consumption Value Market Share by Type (2019-2030)
Figure 59. Middle East and Africa Large Molecule Drugs CDMO Consumption Value Market Share by Application (2019-2030)
Figure 60. Middle East and Africa Large Molecule Drugs CDMO Consumption Value Market Share by Country (2019-2030)
Figure 61. Turkey Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 62. Saudi Arabia Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 63. UAE Large Molecule Drugs CDMO Consumption Value (2019-2030) & (USD Million)
Figure 64. Large Molecule Drugs CDMO Market Drivers
Figure 65. Large Molecule Drugs CDMO Market Restraints
Figure 66. Large Molecule Drugs CDMO Market Trends
Figure 67. Porters Five Forces Analysis
Figure 68. Manufacturing Cost Structure Analysis of Large Molecule Drugs CDMO in 2023
Figure 69. Manufacturing Process Analysis of Large Molecule Drugs CDMO
Figure 70. Large Molecule Drugs CDMO Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
